Bivalos

car and machinery, as well as cognitive functions.

Bivalos is a drug that is used to treat osteoporosis in postmenopausal women. The drug is produced in France, in Servier laboratories, and it belongs to the group of drugs for the treatment of osteoporosis.

The main active ingredient in Bivalos is strontium ranelate. This component helps increase bone density and reduce the risk of vertebral and hip fractures in postmenopausal women. The dosage form of Bivalos is a powder for the preparation of an oral suspension in a dosage of 2 g of active substance in one sachet. The drug also contains excipients: aspartame (E951), maltodextrin and mannitol.

Bivalos has several contraindications for use. The drug is not recommended for use in patients with hypersensitivity to strontium ranelate or any other component of the drug. Bivalos should also be used with extreme caution in patients at high risk of thromboembolism and in patients with severe renal failure. The drug is not intended for the treatment of pregnant and lactating women, as well as children and adolescents.

Taking Bivalos may cause some side effects such as nausea, diarrhea, headache and skin irritation. These effects are usually mild and short-lived, so discontinuation of the drug is not required.

It is also worth considering possible interactions of Bivalos with other drugs. For example, milk and dairy products, as well as medications containing calcium, can reduce the bioavailability of strontium ranelate by approximately 60-70%. When prescribing antibiotics from the group of tetracyclines or quinolones, treatment with Bivalos should be suspended. However, simultaneous use of antacids and Bivalos is allowed.

In general, Bivalos is an effective and safe drug for the treatment of osteoporosis in postmenopausal women, subject to the recommended dosages and rules of administration. However, before starting treatment, you must consult your doctor and become familiar with all contraindications and possible side effects.